Compare Health Care Select Sector SPDR Fund (XLV) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Health Care Select Sector SPDR Fund vs Xpeng Inc - ADR — how do they compare? Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 4.7× Xpeng Inc - ADR's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Health Care Select Sector SPDR Fund for 100 Days and Xpeng Inc - ADR for 80 Days on average.
| XLV | XPEV | |
|---|---|---|
Market Cap | $43.48B | $9.16B |
Volume | 11,121,431 | 5,030,325 |
52-Week High | $175.68 | $28.07 |
52-Week Low | $141.95 | $9.25 |
Typical Hold Time | 100 Days | 80 Days |
Sector | — | Consumer Cyclical |
Enterprise Value | — | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
XPeng (XPEV) trades at $9.55, down 0.31% with bearish technical signals despite analyst optimism. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a -$1.14B net loss. Recent vehicle deliveries of 41,256 units in September 2026 and upcoming G9L SUV launch at Paris Motor Show highlight expansion efforts. Cash flow improved significantly with $8.26B from operations in 2025, though negative earnings surprises in Q1 and Q2 2026 raise execution concerns.
XPeng presents a high-risk growth opportunity with 58.8% analyst buy ratings and $17.55 price target suggesting 84% upside. However, persistent losses, competitive EV market pressures, and technical bearishness create significant headwinds. The stock's appeal hinges on successful Physical AI and robotics commercialization alongside sustained delivery growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
